Eight receptors, one engineered peptide.
A classical drug aims at one receptor and hopes the rest of the body does not notice. A new generation of peptide medicines broke that rule on purpose: tirzepatide engages two receptors, retatrutide three. Panacea Bio Chem's Octogonist programme asks the design question at its limit: what would it take for one amino acid chain to engage eight?
Agonism, from the ground up
Receptors are the cell's antennas — proteins that read chemical signals and convert them into action. The vocabulary of modern pharmacology begins with two words.
Agonist — the switch-on
An agonist binds a receptor and activates it, standing in for the body's own signal. Insulin, adrenaline and GLP-1 all act through receptors; the medicines built on them are agonists.
Antagonist — the blockade
An antagonist occupies the same docking site but flips nothing: it physically prevents the natural signal from getting through. Beta-blockers and antihistamines are everyday examples.
Selectivity — the classic bargain
For a century the art of drug design was narrowing: one molecule, one receptor, minimal cross-talk. Fewer targets meant fewer surprises — and, often, less reach than a disease demands.
Polyagonism — the deliberate opposite
Metabolic and neurological diseases are network problems. Morphy and Rankovic formalised the counter-strategy in 2005: design one ligand to engage several receptors on purpose — a "designed multiple ligand" (J. Med. Chem. 2005).
The Octogonist programme
At Panacea Bio Chem, Bogdan Dicoias runs an amino acid chain (AAC) design practice: sequences are engineered residue by residue, folded, and profiled against receptor panels. The Octogonist series takes that practice to the number the field has not attempted: eight receptors engaged by one engineered peptide — not as eight drugs in a cocktail, but as one chain whose surface is tuned, position by position, to a chosen eight-receptor constellation.
Honesty boundary: this is a design-stage research programme. We publish the concept, the public science it stands on, and the design philosophy — we do not claim a finished molecule, binding data, or any clinical result here. The specific receptor constellation and sequence work remain Panacea intellectual property while the programme matures.
Illustrative programme disclosure · no results are claimed on this page
"The field counted one, then two, then three — and each step looked excessive until it worked. We do not assume the counting stops at three. An amino acid chain has enough addressable surface to speak to more than one receptor; the craft is choosing which eight voices belong in one chord, and tuning every residue so the chord holds."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
Counting receptors: the numbered era
The peptide field now counts receptors the way the space race counted engines — and every number so far has been earned in public.
Two — tirzepatide (GIP + GLP-1)
- Eli Lilly's tirzepatide is a single peptide engineered to activate both the GIP and GLP-1 receptors — the "twincretin".
- SURPASS-2 (Frías et al., NEJM 2021): superior glucose control to semaglutide in type 2 diabetes (trial record).
- SURMOUNT-1 (Jastreboff et al., NEJM 2022): up to ~20.9% mean body-weight reduction over 72 weeks (trial record). Approved by the FDA as Mounjaro (2022) and Zepbound (2023).
Three — retatrutide (GIP + GLP-1 + glucagon)
- Retatrutide adds the glucagon receptor — one peptide, three metabolic receptors. Phase 2 (Jastreboff et al., NEJM 2023): up to ~24.2% mean weight reduction at 48 weeks (trial record).
- Phase 3 TRIUMPH-4 (Lilly, December 2025): ~28.7% mean weight loss at 68 weeks, the first successful phase 3 for a triple agonist (Lilly announcement).
- Matthias Tschöp and Richard DiMarchi call this "unimolecular polypharmacology" — one molecule reading a multi-receptor chord (Nat. Rev. Drug Discov. 2022).
What we show, and what we hold back
This page presents a research direction, not a product. The named medicines above belong to their makers, whose published trials we cite and credit; Panacea's own programme is disclosed at concept level.
Shown
The pharmacology of agonism, the credited history of multi-receptor ligands, the public trial record of dual and triple agonists, and the design reasoning behind pursuing eight.
Held back
The eight target receptors, sequences, folding routes and assay results. A programme of this kind earns its claims in the literature, not on a webpage — disclosure follows data.
Frequently asked questions
What is a receptor agonist?
A molecule that binds a receptor and switches it on, mimicking the body's own signal. An antagonist binds the same site and blocks the signal instead.
What is a multi-receptor agonist?
One molecule engineered to activate several receptors at once — a designed multiple ligand. Tirzepatide (two) and retatrutide (three) are the clinical landmarks.
Does an eight-receptor agonist exist as a medicine?
No approved medicine engages eight receptors by design; the clinical frontier today is triple agonism. Panacea's Octogonist series is a design-stage programme, presented as such.
Who pioneered multi-agonist peptides?
Morphy and Rankovic formalised designed multiple ligands in 2005; Tschöp and DiMarchi advanced unimolecular polypharmacology; Eli Lilly brought tirzepatide and retatrutide to the clinic. The credited timeline is on The Research. More on the Questions page.
Trending in the field
Recent developments in the field — refreshed 2026-07-26 by Panacea Bio Chem.
